Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TARCEVA | OSI Pharmaceuticals | N-021743 DISCN | 2004-11-18 | 3 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
erlotinib | ANDA | 2024-11-28 |
erlotinib hydrochloride | ANDA | 2024-06-10 |
tarceva | New Drug Application | 2018-12-12 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
non-small-cell lung carcinoma | — | D002289 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 2 | 12 | 2 | — | — | 15 |
Lung neoplasms | D008175 | — | C34.90 | 2 | 9 | 2 | — | — | 12 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 5 | 1 | — | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 1 | 6 | — | — | — | 7 |
Squamous cell carcinoma | D002294 | — | — | 1 | 5 | — | — | — | 6 |
Neoplasms | D009369 | — | C80 | 3 | 2 | — | — | — | 5 |
Head and neck neoplasms | D006258 | — | — | 1 | 3 | — | — | — | 4 |
Colorectal neoplasms | D015179 | — | — | — | 3 | — | — | — | 3 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 2 | — | — | — | 3 |
Ependymoma | D004806 | — | — | — | 2 | — | — | — | 2 |
Recurrence | D012008 | — | — | — | 2 | — | — | — | 2 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 1 | — | — | — | 2 |
Glioma | D005910 | EFO_0000520 | — | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharyngeal neoplasms | D010610 | — | C14.0 | 1 | — | — | — | — | 1 |
Drug common name | Erlotinib |
INN | erlotinib |
Description | Erlotinib is a quinazoline compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions. It has a role as an antineoplastic agent, a protein kinase inhibitor and an epidermal growth factor receptor antagonist. It is a member of quinazolines, a terminal acetylenic compound, an aromatic ether and a secondary amino compound. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1 |
PDB | — |
CAS-ID | 183321-74-6 |
RxCUI | — |
ChEMBL ID | CHEMBL553 |
ChEBI ID | 114785 |
PubChem CID | 176870 |
DrugBank | DB00530 |
UNII ID | J4T82NDH7E (ChemIDplus, GSRS) |